Skip to main content
Vcanbio Cell & Gene Engineering Corp., Ltd logo

Vcanbio Cell & Gene Engineering Corp., Ltd — Investor Relations & Filings

Ticker · 600645 ISIN · CNE000000545 LEI · 300300FLWFDJPQYVAZ24 Shanghai Stock Exchange Professional, scientific and technical activities
Filings indexed 2,580 across all filing types
Latest filing 2018-02-23 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 600645

About Vcanbio Cell & Gene Engineering Corp., Ltd

https://www.vcanbio.com/

Vcanbio Cell & Gene Engineering Corp., Ltd. specializes in the fields of cell therapy, gene technology, and precision medicine. The company operates a comprehensive business model centered on the storage of hematopoietic and mesenchymal stem cells, providing long-term bio-banking services for cord blood and other biological tissues. Its technical portfolio includes advanced genetic testing services, such as prenatal screening and oncology diagnostics, alongside the development of cell-based therapeutic products. Vcanbio maintains a network of specialized laboratories and storage facilities to support clinical research and personalized healthcare applications. The organization focuses on translating biotechnological advancements into clinical solutions, emphasizing quality control in cell processing and genomic analysis to serve the evolving needs of the regenerative medicine and diagnostic sectors.

Recent filings

Filing Released Lang Actions
对外担保责任解除的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement from a company regarding the release of external guarantee responsibilities. It details the history of guarantees provided, the repayment and release of guarantee obligations, and the current status of guarantees. The document is short (1267 characters) and focuses on a specific corporate action related to guarantees, not on financial results, management changes, or regulatory filings. It is not a full financial report, audit report, or earnings release. It is an announcement about a capital/financing related matter (guarantees and their release). Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2018-02-23 Chinese
2018年第三次临时股东大会会议资料
AGM Information Classification · 100% confidence The document is titled as the materials for the 2018 third extraordinary shareholders meeting (临时股东大会) of Zhongyuan Xiehe Cell Gene Engineering Co., Ltd. It includes detailed meeting agenda, voting procedures, and a specific proposal regarding the transfer of 6.483% equity in Beijing Genomics Co., Ltd. The document contains detailed transaction terms, shareholder voting, and legal opinions related to the equity transfer. It is clearly a set of meeting materials prepared for a shareholders meeting, not a financial report, earnings release, or announcement of voting results. The content is consistent with presentations and materials shared during a shareholders meeting, which fits the definition of AGM Information (AGM-R). The document length is substantial (over 11,000 characters), indicating it is the actual meeting materials, not just an announcement of a report. Therefore, the correct classification is AGM Information (AGM-R).
2018-02-23 Chinese
2018年第二次临时股东大会的法律意见书
Regulatory Filings
2018-02-22 Chinese
2018年第二次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed announcement of resolutions passed at a shareholders' meeting, specifically the 2018 second extraordinary general meeting of Zhongyuan Xiehe Cell Gene Engineering Co., Ltd. It includes voting results on multiple proposals related to issuance of shares, asset purchase, fundraising, and related transactions. The content focuses on the voting outcomes and meeting details rather than presenting financial statements or management discussion. This matches the definition of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is substantial and contains detailed voting data, not just a brief announcement or a report publication notice. Therefore, it is not a Report Publication Announcement (RPA) or Regulatory Filing (RNS). It is not a full Annual Report, Interim Report, or Earnings Release, nor is it a management or board change announcement. Hence, the best classification is DVA with high confidence.
2018-02-22 Chinese
2018年第一次临时股东大会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the convening, procedures, and results of a company's 2018 first extraordinary general meeting of shareholders. It details the legality and compliance of the meeting's notice, attendance, voting procedures, and resolutions passed. The document does not contain financial statements or performance data but focuses on the legal validation of the shareholder meeting and its voting results. This type of document is typically classified as a Declaration of Voting Results & Voting Rights Announcements (DVA) because it reports official voting outcomes and meeting procedural compliance.
2018-02-14 Chinese
2018年第一次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an announcement of the resolutions from an Extraordinary General Meeting (EGM) held on February 14, 2018, by 中源协和细胞基因工程股份有限公司. It details the meeting attendance, voting results, and legal witness statements. The content focuses on the decisions made at the shareholders' meeting, specifically the appointment of a new supervisor. The document is short (1404 characters) and serves as an official announcement of voting results rather than a full report or presentation. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2018-02-14 Chinese

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.